Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 16,024 as of Friday, Nov. 22, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,437 issues advancing vs. 1,443 declining with 136 unchanged. The Health Services industry currently sits down 0.1% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Boston Scientific ( BSX), up 0.8%, Cigna ( CI), up 0.7% and Fresenius Medical Care AG & Co. KGaA ( FMS), up 0.5%. On the negative front, top decliners within the industry include Covance ( CVD), down 1.2%, DaVita HealthCare Partners ( DVA), down 1.1%, Grifols ( GRFS), down 0.8% and St Jude Medical ( STJ), down 0.5%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. WuXi PharmaTech (Cayman ( WX) is one of the companies pushing the Health Services industry higher today. As of noon trading, WuXi PharmaTech (Cayman is up $0.72 (2.2%) to $33.00 on average volume. Thus far, 294,282 shares of WuXi PharmaTech (Cayman exchanged hands as compared to its average daily volume of 506,500 shares. The stock has ranged in price between $32.30-$33.31 after having opened the day at $32.30 as compared to the previous trading day's close of $32.28. Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. WuXi PharmaTech (Cayman has a market cap of $2.3 billion and is part of the health care sector. The company has a P/E ratio of 21.6, above the S&P 500 P/E ratio of 17.7. Shares are up 105.0% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate WuXi PharmaTech (Cayman a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates WuXi PharmaTech (Cayman as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full WuXi PharmaTech (Cayman Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.